Frontal Fibrosing Alopecia – FFA
Frontal fibrosing alopecia (FFA) is regarded as a distinct clinical variant of lichen planopilaris (LPP) and is a form of primary lymphocytic cicatricial alopecia. It is marked by a steady backward recession of the frontotemporal hairline, with permanent destruction of hair follicles and a band of scarred, atrophic skin. It mainly affects postmenopausal women, although it is being reported more and more often in younger women and in men in recent years.
FFA arises from a complex interplay of cell-mediated autoimmunity, hormonal changes and environmental or contact chemical factors:
- Autoimmune attack on hair follicle stem cells: Activated CD8+ T cells form a band-like infiltrate that targets the bulge region, home to the follicle's stem cells. This interface inflammation destroys the bulge, so the follicle permanently loses its ability to regrow hair and is replaced by scar tissue.
- Role of androgens and estrogen: The strong predominance in postmenopausal women points to an important role for falling estrogen or an estrogen–androgen imbalance. Increased androgen sensitivity of frontal hair follicles also helps drive the disease.
- Reduced PPAR-γ signaling: As in LPP, lower expression of the nuclear receptor PPAR-γ disrupts lipid metabolism in sebaceous glands and follicles, causing lipotoxicity and promoting dermal fibrosis.
- Environmental (contact chemical) hypothesis: Although still debated, many epidemiological studies have linked FFA with regular use of chemical sunscreens (containing avobenzone or octocrylene), facial skincare products or fragrances. These chemicals may act as a hapten that triggers an autoimmune reaction in frontal hair follicles.
At Haute-Derma, managing FFA depends on spotting it early, when the hairline has only just begun to recede or the only sign is eyebrow loss, so we can calm the inflammation in time and preserve as much of the original hairline as possible.
Clinical Features and Differential Diagnosis
FFA, as a form of lichen planopilaris, has very characteristic signs on the face and scalp:
- Band-like receding frontotemporal hairline: The hairline at the forehead and both temples gradually moves back by anywhere from 1 cm to several centimeters. The newly exposed forehead skin is smooth, shiny, thin and paler than the rest of the forehead (the "two-tone forehead" sign).
- Eyebrow loss (madarosis): The earliest and most typical sign, seen in 75–80% of patients. It usually starts in the outer third of the brow and spreads across the whole eyebrow, sometimes years before the hairline recedes noticeably. Patients may also lose eyelashes, underarm hair or hair on the arms and legs.
- Facial papules: Small, smooth, non-itchy, skin-colored bumps on the temples and cheeks, reflecting inflammation of facial vellus hair follicles.
- Lonely hair sign: One or a few isolated hairs left standing on forehead skin where the original hairline used to be.
- Trichoscopy findings:
- Complete loss of follicular openings in the area where the hairline has receded.
- Perifollicular scale (casts) and perifollicular erythema clearly visible along the active edge of the hairline.
- Faint, linear dilated vessels in the atrophic, scarred skin.
How Haute-Derma Diagnoses and Treats FFA
- Clinical diagnosis, trichoscopy and biopsy: The doctor uses trichoscopy to judge how active the inflammation is along the hairline. When needed, or when the picture is atypical, a 4 mm scalp punch biopsy is taken from the advancing edge to confirm lymphocytic inflammation around the upper follicle and concentric perifollicular fibrosis.
- Multi-layered combination medical therapy:
- 5-alpha-reductase inhibitors (finasteride/dutasteride): Considered the most effective mainstay of FFA treatment. Dutasteride (0.5 mg daily or 0.5 mg three times a week) halts hairline recession in most patients by blocking androgen conversion in the follicle.
- Hydroxychloroquine (HCQ): Used when inflammation is markedly active (red margin, thick scale) to calm the chronic autoimmune reaction.
- Topical and intralesional corticosteroids (ILTAC): Low-concentration triamcinolone acetonide (2.5–5 mg/mL) is injected along the inflamed hairline or into the eyebrows to relieve symptoms quickly and stop progression.
- Topical calcineurin inhibitor (tacrolimus 0.1%): Applied to the frontal hairline, eyebrows or facial papules as safe maintenance therapy without the risk of skin atrophy.
- JAK inhibitors (tofacitinib/baricitinib): An advanced targeted option for rapidly progressing FFA, extensive eyebrow loss or disease that has not responded to standard treatment.
- Lifestyle changes and restorative aesthetics:
- We advise patients to stop chemical sunscreens or switch to purely mineral ones (zinc oxide/titanium dioxide), and to limit heavily fragranced products on the forehead.
- Once the disease is fully stable (no inflammatory activity for 12–24 months), eyebrow microblading or micropigmentation can be considered to improve facial appearance.
Comparing FFA With Other Causes of Frontal Hair Loss
| Frontal fibrosing alopecia (FFA) | Androgenetic alopecia (AGA) | Traction alopecia |
|---|---|---|
| Scarring alopecia (follicular openings lost). | Non-scarring alopecia (follicles miniaturize). | Late scarring from chronic mechanical pulling. |
| Eyebrows frequently lost (75–80%). | Eyebrows unaffected. | Eyebrows unaffected. |
| Scale encasing the hair shaft, red-violet margin. | No scale and no redness. | Broken baby hairs and pustules from pulling. |
